Filing Flows › Aptargroup (ATR) › Guidance & outlook
Aptargroup (ATR) guidance and outlook
Aptargroup (ATR) raised its guidance on Oct 29, 2026: EPS $1.52 for Q4 2026; Tax rate 17.5%–19.5% for Q4 2026; EPS $1.12 for Q4 2026. Aptargroup's 10-Q filed Oct 30, 2026 makes 6 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EPS | Q4 2026 | $1.52 | raised |
| Tax rate | Q4 2026 | 17.5%–19.5% | new |
| EPS | Q4 2026 | $1.12 | new |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- Core sales of our products to the prescription drug market decreased 7% primarily due to the anticipated reduction in emergency medicine sales, partially offset by growth in central nervous system therapeutics and asthma/COPD applications.
- Our Outlook is also provided on a non-U.S.
- We expect adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47.
- Our total 2026 estimated cash outlays for capital expenditures net of government grant proceeds are expected to be approximately $260 million to $280 million.
- Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, Contingencies and Outlook sections of this Form 10-Q.
- • our ability to successfully implement facility expansions and new facility projects;
Aptargroup's latest quarter
Aptargroup, Q3 2026: revenue $1.0B (+6% year over year), operating margin 13.2%, net earnings $32.8M, operating cash flow $168M. The chart follows the revenue to costs, profit and cash.
Questions
Did Aptargroup raise or lower its guidance?
Aptargroup (ATR) raised its guidance on Oct 29, 2026: EPS $1.52 for Q4 2026; Tax rate 17.5%–19.5% for Q4 2026; EPS $1.12 for Q4 2026.
What does Aptargroup expect?
Core sales of our products to the prescription drug market decreased 7% primarily due to the anticipated reduction in emergency medicine sales, partially offset by growth in central nervous system therapeutics and asthma/COPD applications. Our Outlook is also provided on a non-U.S. We expect adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.